An objective response among the ALL models was observed in the ALL-2 model that harbors a mutation in the first amino acid of the FLT3 juxtamembrane domain (Y572S, 0.62 VAF) that is predicted to be activating (Dolai et al., 2016), and it showed a PR to sunitinib (Maris et al., 2008). This evidence concerns the gene FLT3 and acute lymphoblastic leukemia.